Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-13 of 13
Keywords: Bisphosphonates
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Journal:
Breast Care
Breast Care (2019) 14 (2): 103–110.
Published Online: 30 April 2019
... Chemotherapy Bisphosphonates Denosumab Breast surgery Sentinel node Axillary dissection Radiotherapy Targeted therapy The St. Gallen Consensus Conference 2019 (March 20–23) was held in Vienna, Austria, for the third time. Giuseppe Curigliano and Eric Winer chaired the panel discussion...
Journal Articles
Journal:
Breast Care
Breast Care (2017) 12 (2): 101–106.
Published Online: 26 April 2017
... situations; adjuvant therapy: bisphosphonates as standard for postmenopausal women. There was no clear panel opinion on the optimal use of multigenomic assays. As always, the panel recommendations are strictly opinion-based, and try to depict the ‘usual' treatment for the ‘average' patients. This rapid...
Journal Articles
Journal:
Breast Care
Breast Care (2015) 10 (2): 124–130.
Published Online: 01 February 2015
... and endocrine treatment, chemotherapy, targeted therapy, as well as adjuvant bisphosphonate use. This report is not aimed to replace the official St. Gallen consensus publication - some recommendations may even be altered in the final paper - but should serve as a preliminary rapid report of this important...
Journal Articles
Journal:
Breast Care
Breast Care (2014) 9 (5): 332–336.
Published Online: 23 October 2014
... of denosumab over bisphosphonates (e.g., zoledronate) for the prevention of SREs. The present review discusses the adverse event profile of these agents, and addresses the prevention and management of untoward side effects. Adverse events associated with osteoclast inhibitors comprise osteonecrosis of the jaw...
Journal Articles
Journal:
Breast Care
Breast Care (2014) 9 (5): 323–330.
Published Online: 20 October 2014
...Simon P. Gampenrieder; Gabriel Rinnerthaler; Richard Greil Bone-targeted therapies like bisphosphonates (zoledronic acid or pamidronate) or denosumab are recommended in all patients with metastatic breast cancer and bone metastases, whether they are symptomatic or not. The choice between these 2...
Journal Articles
Journal:
Breast Care
Breast Care (2014) 9 (5): 319–322.
Published Online: 01 May 2014
... morbidity and mortality. The therapy of bone metastases and osteoporosis with bisphosphonates (BPs) has been established many years ago as a standard treatment. In the adjuvant setting, cancer treatment-induced bone loss is a frequent cause of morbidity, and prevention and treatment of this condition...
Journal Articles
Journal:
Breast Care
Breast Care (2013) 8 (2): 102–109.
Published Online: 01 February 2013
... of the 2013 international panel voting procedures with regard to loco-regional and endocrine treatment, chemotherapy, targeted therapy as well as adjuvant bisphosphonate use. This report is not aimed to replace the official St. Gallen Consensus publication, some recommendations may even be altered...
Journal Articles
Michael Gnant, Marija Balic, Edgar Petru, Wolfgang Raunik, Christian F. Singer, Guenther G. Steger, Ingeborg M. Watzke, Thomas Brodowicz
Journal:
Breast Care
Breast Care (2012) 7 (2): 92–98.
Published Online: 01 February 2012
... approaches for oncological diseases and the resulting improvements of median overall survival, the aim of preventing and delaying the occurrence of SREs becomes more important. To avoid, wherever possible, therapies requiring hospitalization, is another relevant goal. In recent years, bisphosphonates, along...
Journal Articles
Journal:
Breast Care
Breast Care (2011) 6 (2): 136–141.
Published Online: 29 April 2011
... of the 2011 international panel voting procedures with regard to locoregional and endocrine treatment, chemotherapy, targeted therapy as well as adjuvant bisphosphonate use. © 2011 S. Karger AG, Basel 2011 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication...
Journal Articles
Journal:
Breast Care
Breast Care (2010) 5 (5): 298–304.
Published Online: 29 October 2010
...Michael Gnant Adjuvant bisphosphonate therapy is increasingly used in postmenopausal breast cancer patients. This is based on level-one evidence that bisphosphonates, particularly zoledronic acid, can effectively prevent cancer treatmentinduced bone loss in breast cancer patients receiving...
Journal Articles
Journal:
Breast Care
Breast Care (2010) 5 (5): 306–311.
Published Online: 27 October 2010
... survival time of 3–4 years. The treatment goal at this stage of the disease comprises improvement of quality of life, and reduction of bone pain and typical complications like fractures and hypercalcemia. By consistent use of bisphosphonates these goals can be accomplished. Bisphosphonates improve bone...
Journal Articles
Journal:
Breast Care
Breast Care (2010) 5 (5): 320–325.
Published Online: 15 October 2010
...-induced bone loss (CTIBL). Furthermore, bone metastases are commonly found in advanced disease. Current treatment options for bone lesions comprise systemic anti-tumour therapy, irradiation, surgery and bisphosphonates. The main mechanism of osteolysis, osteoclast activation, is induced by the RANK ligand...
Journal Articles
Journal:
Breast Care
Breast Care (2008) 3 (5): 311–316.
Published Online: 17 October 2008
... results. In contrast, the use of adjuvant bisphosphonates may offer another strategy of further improving clinical outcomes in this important patient subgroup. Breast Care Review Article · Übersichtsarbeit Breast Care 2008;3:311 316 DOI: 10.1159/000156985 Published online: October 17, 2008 Adjuvant...